News coverage about Onconova Therapeutics (NASDAQ:ONTX) has trended positive on Tuesday, Accern Sentiment reports. The research group ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Onconova Therapeutics earned a daily sentiment score of 0.28 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.7942329131881 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
- $410,000.00 in Sales Expected for Onconova Therapeutics, Inc. (ONTX) This Quarter (americanbankingnews.com)
- ONCONOVA THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K) (4-traders.com)
- Onconova Therapeutics Announces Publication of Results from Phase 1/2 Study of Rigosertib in Patients with Myelodysplastic Syndromes (MDS) and MDS Progressed to Acute Myeloid Leukemia (finance.yahoo.com)
- Onconova Therapeutics Announces Data on Improved Formulation of Rigosertib and Next-Generation CDK4/6 Inhibitor at 2017 American Association of Pharmaceutical Scientists Annual Meeting (finance.yahoo.com)
- Head to Head Review: Onconova Therapeutics (ONTX) & Alimera Sciences (ALIM) (americanbankingnews.com)
Onconova Therapeutics (NASDAQ ONTX) opened at $1.70 on Tuesday. Onconova Therapeutics has a 12 month low of $1.46 and a 12 month high of $3.88.
Onconova Therapeutics (NASDAQ:ONTX) last posted its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.73) by $0.02. The company had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.29 million. Onconova Therapeutics had a negative return on equity of 558.97% and a negative net margin of 2,855.94%. equities analysts anticipate that Onconova Therapeutics will post -3.06 EPS for the current fiscal year.
Several research firms have recently weighed in on ONTX. Maxim Group restated a “buy” rating and set a $6.00 price target on shares of Onconova Therapeutics in a report on Thursday, November 2nd. Dawson James restated a “buy” rating on shares of Onconova Therapeutics in a report on Tuesday, July 25th. HC Wainwright restated a “buy” rating on shares of Onconova Therapeutics in a report on Thursday, November 9th. Finally, ValuEngine upgraded Onconova Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $7.33.
ILLEGAL ACTIVITY NOTICE: “Onconova Therapeutics (ONTX) Earns Daily News Sentiment Rating of 0.28” was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://ledgergazette.com/2017/11/21/onconova-therapeutics-ontx-earns-daily-news-sentiment-rating-of-0-28.html.
Onconova Therapeutics Company Profile
Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.
Receive News & Ratings for Onconova Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.